

PRESS INFORMATION



CytoTools

The CytoTools AG announces a strengthening of senior management, as well as capital measures at the level of DermaTools Biotech GmbH, the most important subsidiary

- The CytoTools AG has made personnel decisions at DermaTools for the medical products development, and the promising repeat of the clinical phase III trial
- Dr. Patrik Scholler takes over the newly created post in the field of medical products and strategic business development, a field in which he has many years of successful management experience
- The field of clinical development and medicine has been taken over by the experienced manager Dr. Henri Kool van Langenberghe, who, as a senior manager, has successfully carried out international development projects
- The existing shareholders of DermaTools approve capital measures of over half a million euros in order to prepare the inclusion of new shareholders

Darmstadt, 2nd August 2017 – The CytoTools AG, a technology holding with participations in the pharmaceutical and medical products fields, announces a strengthening of the executive management of the DermaTools Biotech GmbH. We were able to secure the services of a very experienced manager from the medtech field for the newly created business sector: medical products and strategic business development. With immediate effect, Dr. Patrik Scholler is available for this key position. During his career, Dr. Scholler has held a series of senior positions in life sciences and medtech companies, both in startups as well as international concerns. Among others, he was active in senior strategic functions at GE Healthcare and Drägerwerk. In his last positions, as CEO of biotech companies, he was involved in the development of new drugs. His appointment to this new position supports our important target of making the newly started project, „medical products“, evolve into a rapid market success together with partners.

At the current time, in which the phase III trials for DermaPro[®] are being repeated, it is decisively important for the CytoTools AG to have an experienced clinical manager for this position, who will personally accompany the complete duration of the trials and the registration process. With Dr. Henri Kool van Langenberghe, we have been successful in recruiting a top manager from the pharmaceutical development field for this task. Over the past years, Dr. Kool van Langenberghe has worked for a Swiss company where he successfully supervised a large international phase III trial with more than 2000 patients.

His main assets are his sound practical experience in the management of clinical trials and the development of pharmaceutical and medical products. In the past, Dr. Kool van Langenberghe worked for one Italian and two Swiss companies at top management and CEO levels. Furthermore, he was able to gain management experience in one of the largest clinical research organisations in the world. Thus, the CytoTools company has now set up the prerequisites for bringing the DermaPro® project to a successful conclusion by repeating the clinical phase III trials.

A series of capital measures were taken in order to prepare for the inclusion of further capital into the DermaTools Biotech GmbH for a total sum of over half a million euros. With these measures, and the accompanying resolutions, the path has been prepared for including new investors in the shareholding structure. The negotiations have reached an advanced level. The intention is to begin with the completion of the financing for the repeat of the phase III trials after the coming annual general meeting of the CytoTools AG.

This press release contains specific future oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future-oriented statements made. CytoTools is not obligated to update these future-oriented statements.

CytoTools AG, previously CytoTools GmbH, is a technology holding and participating company which holds shares in its subsidiary companies with product developments in the pharmaceutical and medical products fields: about ca. 57 % of the DermaTools Biotech GmbH (therapy field dermatology, urology) and 42 % of the CytoPharma GmbH (therapy field cardiovascular disease, cancer). The complete know-how is protected by corresponding basic patents which are maintained worldwide and which are transferred to the subsidiary companies in the form of worldwide exclusive licenses

Contact:

CytoTools AG
Dr. Mark-André Freyberg
Klappacher Str. 126
D-64285 Darmstadt
Tel.: +49-6151-95158-12
Fax: +49-6151-95158-13
E-Mail: freyberg@cytotools.de